【摘要】 目的　探讨不同剂量血脂康治疗合并有脂质代谢异常的冠心病患者的量效关系及其安全性。方法　将 2 5 5例冠心病患者随机分为 5个剂量组记录服药前及服药后第 1、3、6个月服药反应与化验指标 ,同时观察各剂量组中CHD患者TC、LDL—C和TC的达标率情况。结果　 ( 1 )血脂康可显著降低合并有脂质代谢异常的冠心病患者TC、LDL—C和TG水平并显著升高HDL—C水平。同一剂量血脂康治疗时随着时间的延长效应逐渐增大 ,并多在第 3个月达高峰。 ( 2 )除个别情况外 ,在第 1、3、6个月时不同剂量组间CHD患者TC、LDL—C和TG的达标率均有显著差异 ,且不同时间的达标率与对数剂量呈显著的正相关 ,TC、LDL—C的达标率随服药时间的延长而显著增高 ,而TG的达标率则在第 3个月时达到高峰后随服药时间的延长未再显著增高 ;( 3 )副反应发生率为 1 2 1 0 % ( 3 8/ 3 1 4)。结论　 ( 1 )血脂康胶囊治疗脂质代谢异常疗效显著、并呈现出明显的剂量—效应关系 ;( 2 )不同剂量血脂康治疗后的最大疗效出现在治疗后的第 3个月这一时段上 ,此时段可作为疗效判断及调整治疗的时间窗 ;( 3 )血脂康治疗有较好的安全性。更多还原

【Abstract】 Objective To research the dose-effect relation and security of different doses Xuezhikang in coronary heart disease(CHD)patients with abnormal blood lipids metabolism.Methods Tow hundreds and fifty-five CHD patients were randomlg divided into five groups by Xuezhikang dose (0.6/d,0.9/d,1.2/d,1.8/d and 2.4/d,respectively).Before and after applying the first,third,sixth month we recorded the patient’s condition,reaction after applying,the indexes of blood test and the control rates of total Cholesterol(TC),low density 1ipid-C(LDL-C) and Triglycerides(TG)of CHD patients in all groups.Results (1) The levels of TC,LDL-C and TG of CHD patients with abnormal blood lipids metabolism were distinctly decreased and the levels of high density lipid-C(HDL-C)was markedly increased of those patients. The therapy effect of the same dose Xuezhikang could be better with longer treatment period.But the therapy effect couldn’t befurther gain after three months the peak effect.(2) Usually,the control rates of TC,LDL-C and TG in CHD patients of all groups were notablely different in the first,third and sixth month,and the control rates of different periods appeared positive correlation to LOG dose.The TC and LDL-C control rates could be promoted prominently with longer treatment period.Inversely,the TG control rates couldn’t be gain after three months.(3) The morbidity of whole side-effect was 12.10%.Conclusion (1) The therapy effect of Xuezhikang was sure in CHD patients with blood lipids metabolism abnormal and showed the clear dose-effect relation。(2) The third month after appnlying could be called“watching window”,the best period of weighing therapy effect and adjusting doses, because the peak effect appeared at this time.(3) There were better security applied Xuezhikang in CHD patients with abnormal blood lipids metabolism.更多还原